Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Reiser

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Nature Immunology|February 13, 2023
Reply to: Apolipoprotein C3 induces inflammasome activation only in its delipidated formStephen Zewinger, Jochen Reiser, Vera Jankowski, et al.
Nature Immunology|December 11, 2019
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activationStephen Zewinger, Jochen Reiser, Vera Jankowski, et al.
Journal of Medical Virology|January 18, 2024
SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19Alexi Vasbinder, Kishan Padalia, Ian Pizzo, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Nature Metabolism|March 29, 2022
Molecular consequences of SARS-CoV-2 liver tropismNicola Wanner, Geoffroy Andrieux, Pau Badia-I-Mompel, et al.
JAMA Internal Medicine|July 16, 2020
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the USShruti Gupta, Salim S Hayek, Wei Wang, et al.
JAMA Internal Medicine|October 20, 2020
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19Shruti Gupta, Wei Wang, Salim S Hayek, et al.
The Journal of Clinical Investigation|October 4, 2022
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosisGeorge Hindy, Daniel J Tyrrell, Alexi Vasbinder, et al.
The Journal of Clinical Investigation|March 7, 2017
CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosusMohd Hafeez Faridi, Samia Q Khan, Wenpu Zhao, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Nature Immunology|February 13, 2023
Reply to: Apolipoprotein C3 induces inflammasome activation only in its delipidated formStephen Zewinger, Jochen Reiser, Vera Jankowski, et al.
Nature Immunology|December 11, 2019
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activationStephen Zewinger, Jochen Reiser, Vera Jankowski, et al.
Journal of Medical Virology|January 18, 2024
SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19Alexi Vasbinder, Kishan Padalia, Ian Pizzo, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Nature Metabolism|March 29, 2022
Molecular consequences of SARS-CoV-2 liver tropismNicola Wanner, Geoffroy Andrieux, Pau Badia-I-Mompel, et al.
JAMA Internal Medicine|July 16, 2020
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the USShruti Gupta, Salim S Hayek, Wei Wang, et al.
JAMA Internal Medicine|October 20, 2020
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19Shruti Gupta, Wei Wang, Salim S Hayek, et al.
The Journal of Clinical Investigation|October 4, 2022
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosisGeorge Hindy, Daniel J Tyrrell, Alexi Vasbinder, et al.
The Journal of Clinical Investigation|March 7, 2017
CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosusMohd Hafeez Faridi, Samia Q Khan, Wenpu Zhao, et al.
Pageof 25